Company intelligence / Profile preview

Nutaria

Ownership: Private
Development stage: Preclinical

Overview

Successfully completed an intranasal study on NT501 at LIOS demonstrating precise delivery to critical brain regions, with significant accumulation of the active ingredient in Parkinson's-associated areas. Planning to initiate further studies with clinical trials scheduled to begin in early 2027[1].

Therapeutic areas: Neurology
Modalities: Intranasal delivery system for nutraceuticals
Industry: Food & Nutrition

Drug pipeline

1 asset

curcumin nanoformulation

Pre-clinical

Indications: Parkinson's disease

Partnerships

IFF/DUPONTLIOS (internationally renowned institute for pharmacological research)Israeli Parkinson's Association[1][3]

Beyond the preview

Go deeper on Nutaria.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nutaria.

Explore the full profile